CHICAGO, Oct. 16 /PRNewswire-USNewswire/ -- In 1984, the American Cancer Society (ACS) inaugurated the National Breast Cancer Awareness Month (NBCAM), with its October 17 flagship National Mammography Day. The NBCAM was conceived and funded by the Imperial Chemical Industries, a leading international manufacturer of petrochemicals, and its U.S. subsidiary Zeneca Pharmaceuticals. Zeneca is the sole manufacturer of Tamoxifen, claimed to reduce risks of breast cancer, even though it is toxic and carcinogenic.
The NBCAM assured women that "early (mammography) detection results in a cure nearly 100% of the time." More specifically, the NBCAM is primarily directed to claims for reducing the incidence and mortality of breast cancer through early detection by annual mammography starting at age 40.
Still unrecognized by the ACS, and also the National Cancer Institute (NCI), is strong evidence that mammography poses significant risks of breast cancer. The routine practice of taking four films annually for each breast results in approximately 1 rad (radiation absorbed dose) exposure, which is approximately 1,000 times the dose from a single chest X-ray. Each rad exposure increases risks of breast cancer by about one percent, with a cumulative 10 percent increased risk for each breast over a decade's screening. Moreover, the premenopausal breast is highly sensitive to radiation. Not surprisingly, premenopausal mammography screening is practiced by no nation other than the U.S.
Risks of premenopausal mammography are some four-fold greater for the one to two percent of women who are carriers of the A-T gene (ataxia telangiectasia), and highly sensitive to the carcinogenic effects of radiation. By some estimates, this accounts for up to 20 percent of all breast cancers diagnosed annually.
Compounding these problems, missed cancers are common in premenopausal women due to the density of their breasts.
That most breast cancers are first recognize
|SOURCE Cancer Prevention Coalition|
Copyright©2007 PR Newswire.
All rights reserved